


INDUSTRY ENGAGEMENT - GENOMICS

Genomics is increasingly being used by Australian industry to fundamentally transform healthcare, food production, agriculture and environmental sustainability.

The impact of DNA-sequencing technology is obvious in diagnosing and treating disease but genomics techniques are also increasing agricultural productivity, facilitating environmentally friendly products and being used to trace commercial species enabling regulation and sustainability decisions.

The Australian Genome Research Facility Ltd (AGRF) is a key partner in the Bioplatforms Australia infrastructure network and provider of genomics services.

AGRF's world-class research capability is publicly accessible and increasingly utilised for commercial applications such as the development of therapeutics, pathology services, breeding programs, quality processes and food safety.




INNOVATION PIPELINE

AGRF supports industries through the entire innovation pipeline translating new knowledge and techniques to applied outcomes. AGRF's commercial users can be broadly categorised into three key areas - discovery, development and service delivery.

Discovery

Powerful genomics techniques are used to discover biological markers that can lead to new products, such as therapeutic or diagnostic products. Discovery activities are performed in collaboration with a diverse range of industry partners including pharmaceutical companies, agricultural breeders and life science testing companies.



Development

AGRF helps to design, develop, validate and implement novel assays for a broad range of applications relevant to pharmaceutical manufacturing, pathology, agriculture and horticulture, genetic testing and forensics. The assays may be used by the client in-house or may be commercialised as a proprietary testing product.

Delivery

As a NATA-accredited laboratory, AGRF commonly develops and performs assays for a client's in-house testing and QC or so they can supply them to their own customer base. These assays may have been independently developed by AGRF and sold to a wide range of industry clients or may be contracted by companies during their product development phase.

CASE STUDIES



CSL

Discovery

CSL, Australia's largest biopharmaceutical company, engages AGRF in several areas including the development of novel antibody-based therapeutics involving transcriptome profiling of blood-cell lineages.



CYTOGENETICS SERVICES

Development & Delivery


Cytogenetics is utilised to detect congenital disorders and diagnose diseases caused by chromosome abnormalities. As a NATA-accredited laboratory, AGRF conducts microarray-based cytogenetic testing for multiple commercial pathology providers in the order of several thousand tests a year. AGRF provides the raw test data to the pathology providers who then apply their proprietary systems for interpretation and reporting. Such contracts provide a cost-effective access to expensive infrastructure and specialist expertise while also providing economy of scale benefits for high throughput instrumentation.



SUGAR RESEARCH AUSTRALIA

Discovery & Development

Sugar Research Australia has utilised AGRF's expertise to develop and implement a DNA finger printing test of sugar cane varieties to build a database which now contains over 400 varieties. AGRF processes more than 1000 samples per annum to identify unknown or disputed varieties and to support breeding and propagation programs.



DNA SECURITY SOLUTIONS

Development & Delivery

DNA Security Solutions is an innovative Australian company that specialises in criminal marking systems. AGRF has been a long-standing collaborator in developing, testing and validating a synthetic DNA-based solution for the company's security products.




BIOPLATFORMS AUSTRALIA

Bioplatforms Australia's infrastructure network provides open access to sophisticated instrumentation that is operated by expert technical staff for academic, research and commercial endeavours.

Our genomics partners regularly collaborate with industry to translate research into productive outcomes.

Value of BPA research infrastructure network to industry

- Rapid and affordable access to world leading talent and infrastructure that is costly to establish, operate and maintain
- Access to expert problem solving
- Transforms research techniques into commercial applications
- Enables product innovation and a competitive edge
- Linkages to academia and a gateway to international collaborations
- Economies of scale via high throughput instrumentation



BIOPLATFORMS AUSTRALIA

Bioplatforms Australia Ltd

Andrew Gilbert
T | 02 9850 6200
M | 0410 538 648
www.bioplatforms.com

Bioplatforms Australia is a non-profit organisation that supports Australian life science research with crucial investments in state-of-the-art 'omics technologies and cutting edge expertise. Investment funding has been provided through the Commonwealth Government National

NCRIS

National Research Infrastructure for Australia
An Australian Government Initiative

Collaborative Research Infrastructure Strategy, 2009 EIF Super Science Initiative and the Collaborative Research Scheme. Co-investments have been made by State Governments, research institutes and commercial entities.